Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy.
OBJECTIVE
The prognosis of ovarian cancer has improved because of platinum- and taxane-containing chemotherapy. We investigated the 5-year disease-specific overall survival and prognostic factors of patients with advanced ovarian cancer to elucidate the change in clinical course of ovarian cancer with the advance of chemotherapy for patients who developed relapse in the era before the addition of molecular targeting therapy.


METHODS
We reviewed the clinical course of 134 patients with advanced ovarian cancer (FIGO Stage III and IV) treated in the past 11 years (1999-2010). We classified the patients into two groups: those who had been diagnosed with ovarian cancer from 1999 to 2005 (Group A) and those who had been diagnosed from 2006 to 2010 (Group B). We compared the 5-year disease-specific overall survival and median survival rates between these two groups. We also investigated the prognostic factors of 104 patients who developed relapse.


RESULTS
The 5-year disease-specific overall survival rate was significantly higher in Group B than A (67.0% vs. 38.6%; P = 0.032). Chemotherapy containing pegylated liposomal doxorubicin hydrochloride, non-clear cell adenocarcinoma and intestinal resection were independent prognostic factors.


CONCLUSIONS
The induction of new chemotherapeutic drugs and the increased variation of second- or third-line chemotherapy affected the improvement in overall survival of patients with advanced epithelial ovarian cancer.
Gynecology Service, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka.
Takako
T
Shimada
Gynecology Service, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka.
Toshiaki
T
Saito
Clinical Research Institute, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka, Japan.
Mototsugu
M
Shimokawa
Gynecology Service, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka.
Kumi
K
Shimamoto
Gynecology Service, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka.
Shuhei
S
Matsushita
Gynecology Service, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka.
Shinichiro
S
Yamaguchi
Gynecology Service, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka.
Kazuya
K
Ariyoshi
Gynecology Service, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka.
Masao
M
Okadome
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003710:Demography; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use; D011379:Prognosis; D000093542:Gemcitabine
C506643:liposomal doxorubicin; D003841:Deoxycytidine; D011092:Polyethylene Glycols; D004317:Doxorubicin; D000093542:Gemcitabine
5-year disease-specific overall survival; advanced ovarian cancer; chemotherapy; recurrence